Matthew D Hellmann

Title: Matthew D. Hellmann: Innovator in Cancer Immunotherapy

Introduction

Matthew D. Hellmann is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, particularly in the area of immunotherapy. His work focuses on understanding how certain molecular determinants can influence the response of cancers to immunotherapy treatments.

Latest Patents

Matthew D. Hellmann holds a patent titled "Determinants of cancer response to immunotherapy by PD-1 blockade." This patent describes the molecular determinants of cancer response to immunotherapy and outlines systems and tools for identifying and characterizing cancers that are likely to respond positively to such treatments. He has 1 patent to his name.

Career Highlights

Matthew is affiliated with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer treatment and research. His work at this prestigious center has allowed him to contribute to groundbreaking advancements in cancer immunotherapy.

Collaborations

He has collaborated with notable colleagues in the field, including Timothy A. Chan and Naiyer A. Rizvi. These collaborations have further enhanced the impact of his research and innovations.

Conclusion

Matthew D. Hellmann is a key figure in the advancement of cancer immunotherapy, with a focus on understanding the molecular factors that influence treatment responses. His contributions are paving the way for more effective cancer therapies.